Local media reports that following three deaths in Yunnan province China's Ministry of Health and State Food and Drug Administration have jointly issued an urgent notice to ban the sale and use of Ciwujia injection produced by Heilongjiang Wandashan Pharmaceutical.

According to the notice serious adverse reactions to the Ciwujia injection appeared in six patients after they received the injection and three of them died, according to the notice. The lot numbers of the two batches of Ciwujia injection involved are 2007122721 and 2007121511.

The Ciwujia injection is mainly used for cardiovascular and cerebrovascular disease and liver and gallbladder disease.

The Ministry of Health and the SFDA have sent two workgroups to Yunnan and Heilongjiang for further investigation and medical treatment.